Effectiveness and implementation of a multidisciplinary lifestyle focused approach in the treatment of inpatients with mental illness (MULTI+): a stepped wedge study protocol

N. M. den Bleijker¹,², M. M. E. van Schothorst¹,³*, I. J. M. Hendriksen⁴, W. Cahn², N. K. de Vries⁵, P. N. van Harten¹,³ and J. Deenik¹,²,³

Abstract

Background: People with mental illness have a reduced life expectancy compared to the general population. Despite the increasing evidence for the efficacy of lifestyle interventions there is little change in routine clinical care. This discrepancy is often referred to as the implementation gap and has caused a need for effectiveness and implementation research in real-world settings. Our study assesses the effectiveness and implementation of a multidisciplinary lifestyle focused approach in the treatment of inpatients with mental illness (MULTI+).

Methods: An open cohort stepped wedge cluster randomized trial in inpatients psychiatric wards of GGz Centraal, the Netherlands. The wards are divided into three clusters based on geographical region. These clusters are randomly allocated to one of the three pre-defined steps to integrate MULTI+. MULTI+ can be tailored to fit individual psychiatric wards and includes 10 core components aimed at improving lifestyle factors. The primary outcome is to investigate the difference in the mean QRISK3 score of patients receiving MULTI+ compared to patients receiving TAU. Secondary outcomes include somatic and mental health outcomes, lifestyle factors, and implementation factors. Findings will be analysed using mixed model analyses.

Discussion: The MULTI+ study is the first large-scale study evaluating the long-term effects of a multidisciplinary, multicomponent approach aimed at improving lifestyle factors in routine inpatient mental health care. A limitation of this study is the risk of missing data due to the large-scale, real-world setting of this study. Furthermore, implementation monitoring and external events that may influence outcomes could be difficult to account for. Strengths of this study are the focus on effectiveness as well as implementation and the inclusion of both patient and health care professionals’ perspectives. Effectiveness studies in routine clinical care can advance our knowledge on lifestyle interventions in real-world settings.

Trial registration: ClinicalTrials.gov registration. Identifier: NCT04922749. Retrospectively registered 3th of June 2021.

*Correspondence: m.vanschothorst@ggzcentraal.nl

¹ Scientific Research Department, GGz Centraal, Amersfoort, the Netherlands

1 Full list of author information is available at the end of the article
Background

People with mental illness (MI) have a reduced life expectancy compared to the general population, mostly attributable to somatic diseases caused by poor physical health [1, 2]. Irrespective of their diagnosis, people with MI have 1.4–2 times higher risk of cardiometabolic diseases (e.g. cardiovascular disease (CVD) and diabetes), many of which can potentially be avoided [3–5]. Modifiable lifestyle factors such as physical activity (PA), diet, sleep and smoking behaviour have been increasingly associated with the onset of somatic diseases in people with MI [3, 5–8]. Adverse health behaviours are prevalent in people with MI and the resulting poor physical health is often exacerbated by the adverse effects of psychotropic medication [9, 10]. Hence, it is important to stimulate healthy lifestyle behaviours in people with MI.

There is increasing clinical and scientific evidence for the efficacy of interventions targeting lifestyle factors [6]. A series of reviews and meta-analyses that analysed interventions aimed at improving PA [11, 12], nutrition and diet [13, 14], sleep [15, 16], and smoking cessation [17] have shown favourable results on cardiometabolic health, psychosocial functioning and quality of life. In addition to this, reductions in MI-related symptoms such as negative symptoms, depression and psychotic symptoms were found. Despite this overwhelming evidence demonstrating the efficacy of interventions aimed at improving lifestyle factors, there have not been many structural changes in routine clinical care for people with MI [5, 18–21].

Implementing and sustaining interventions is an intricate process, and multiple factors can hinder the translation of evidence into practice [20, 22, 23]. For example, efficacy research mostly uses a randomized-controlled trial (RCT) design which can often not be translated linearly into routine clinical care, resulting in diminished effects [24, 25]. Moreover, trials often do not pass research stages, or are less likely to be sustained [22]. Pragmatic clinical trials could promote the implementation and sustainability into routine clinical care because they better reflect real-world conditions [26]. In addition, implementation factors, such as organisational culture and financial sustainment, can complicate the uptake and continuation of lifestyle interventions [27]. Studies investigating implementation factors are scarce, whilst several publications highlight their importance [6, 20, 28, 29]. Consequently, the focus of the present research is on the implementation gap (i.e. how to make it work), rather than a knowledge gap (i.e. does it work?) [20].

The most efficacious lifestyle interventions are delivered by qualified health care professionals (HCPs) and target multiple lifestyle factors simultaneously [5, 29, 30]. However, research on such multidisciplinary, multicomponent lifestyle interventions is scarce and little is known about long-term effects and sustainability. Moreover, most research is conducted in outpatient settings. Further research in inpatient settings is especially important considering the high illness severity and comorbidity in this patient population [31].

Deenik and colleagues [30] previously evaluated a multidisciplinary, multicomponent approach (called MULTI) aimed at a holistic lifestyle change in a real-world inpatient setting for people with severe mental illness (SMI). They found positive changes in both somatic and mental health after 18 months compared to usual care, such as improvements in metabolic risk factors, psychosocial functioning and a reduction in the use of psychotropic medication [32, 33]. The authors urged to confirm and complement findings in scaled-up studies and made several suggestions for improvement of the approach and pragmatic research of implementation [30]. In line with these recommendations, MULTI has been further developed into MULTI+ and will now be implemented on a larger scale. We aim to investigate the effectiveness and implementation of this multidisciplinary lifestyle focused approach in the treatment of inpatients with mental illness (MULTI+).

Methods

Study design and setting

This study is an open cohort stepped wedge cluster randomized trial conducted at all inpatient wards of the specialist mental healthcare organisation GGz Centraal (the Netherlands) [34]. The organisation will implement MULTI+ semi-annually in three geographical regions (clusters). Wards are almost equally distributed per cluster, covering a total of ~830 places of residence in which ~2000 patients are treated annually (Table 1). This gradual implementation intends that all clusters are

| Table 1 | Places of residence divided in three clusters |
|---------|---------------------------------------------|
| Cluster | Wards (n) | Places of residence (n) |
| 1       | 15        | ~300                   |
| 2       | 14        | ~300                   |
| 3       | 15        | ~230                   |
exposed to MULTI+ at the end of this trial. Each step includes a one-month transitional phase to prepare the cluster for the implementation of MULTI+. This trial takes 18 months to complete.

In line with the regional implementation, cluster-level randomisation is used. Individual-level randomisation is not possible because patients cohabit in groups within wards. Moreover, cluster-level randomisation minimizes the risk for contamination between HCPs working in multiple wards or different geographical clusters. Due to high patient turnover the patient population may differ at each measurement and individual follow-up for long-term evaluation is not feasible after discharge.

Measurements are obtained at the same time in all clusters at baseline (T0), after six months (T1), after twelve months (T2) and after eighteen months (T3). Measurements take approximately three months to complete (Fig. 1).

Eligibility criteria
Patients aged ≥ 16 years who receive care at the inpatient psychiatric wards of GGz Centraal are eligible to participate in the study. Patients are not eligible to participate when they have limited knowledge or understanding of the Dutch language, or if their psychiatric or physical condition hinders informed consent at the discretion of the relevant physician, nurses, or researcher.

Intervention
MULTI+ is a multidisciplinary, multicomponent intervention which aims to improve lifestyle factors through a holistic approach. MULTI+ focuses on 10 core components (i.e. the elements and activities that are necessary to achieve desired outcomes) [35], based on previous research and recommendations (Table 2) [5, 14, 30]. MULTI+ is embedded in the long-term policy of the mental health care organisation, creating a support base and resources to facilitate implementation at all organisational levels. The implementation of the core components is co-designed with, and tailored to the ward and patient population, because of the large heterogeneity in patient characteristics and varying access to facilities and staffing.

MULTI+ is implemented gradually in every cluster at ward level between November 2020 and November 2021. The explicit aim is the integration into routine clinical care instead of MULTI+ being a temporary intervention. The chief physicians supervise the implementation. Four to six months before the start of implementation we approach the chief physicians to discuss the practical start with, and integration of the core components.
Because the organizational structure differs between clusters and wards, the practical dissemination and implementation of the core components of MULTI + may be adjusted where needed to promote sustainability. Nonetheless, every ward should have a multicomponent approach and have multidisciplinary consultations with qualified HCPs of relevant disciplines, such as practitioners, nurses, movement therapists and dietitians. HCPs develop active day-to-day programs in multidisciplinary work sessions tailored to their respective psychiatric wards. This day-to-day program includes various activities in accordance with the core components.

It is intended that patients participate in at least two activities per day to decrease sedentary behaviour. HCPs actively participate in these activities. Attending activities together contributes to joint responsibility and group feeling, increases peer support among patients, and facilitates culture change. When possible, patients are involved in designing the activities in the day-to-day program by fitting the activities to their capabilities and interests, to increase their intrinsic motivation. Compliance of patients with the intervention is discussed in multidisciplinary consultation among HCPs and extra support to the patient is provided when needed. The possibilities for co-design and tailoring makes MULTI + uniquely applicable to various forms of daily clinical care.

To establish long-term sustainability, an implementation team is formed to evaluate and safeguard ongoing improvement of MULTI +. This team consists of a senior researcher, a project leader and two junior researchers, and facilitates key activities in the implementation, improvement and continuation of MULTI + [39]. In collaboration with the implementation team, educational resources for HCPs and patients about lifestyle factors are developed to increase knowledge and enhance skills and capabilities. These resources are distributed using company-specific communication channels (such as
internal webpages, e-mail, and teams’ pages), presentations, podcasts, e-learning modules, and webinars. The implementation team works in close collaboration with key stakeholders such as the board of directors, head physicians, nurse advisory board, the client association, and representatives of the family board. Research has shown that implementation teams can guide implementation and ensure faster, more successful outcomes [39].

**Treatment as usual (TAU)**

TAU consists of pharmacological treatment, psychotherapy, and a less structured day-to-day program. Concomitant forms of care may be provided during the study.

**Data collection and management**

Data is obtained from routine screening (from electronic patient files according to the organisational data protocol) and questionnaires. Questionnaire data, including demographics, is collected with Castor EDC [40]. This is a cloud-based electronic research data management platform for the secure collection and management of data. Questionnaires for HCPs are conducted through online surveys. We administer the questionnaires for patients through semi-structured interviews, because inpatients with MI often experience cognitive deficits, which can lead to impaired concentration, memory deficits and poor understanding of questions [41, 42]. Semi-structured interviews allow for the clarification of questions when needed. Due to illness severity and cognitive deficits, not all patients may be able to complete all questionnaires. Patients are included in this study if they complete at least one questionnaire. Conducting all questionnaires takes 45–60 min per patient, which can be completed in multiple appointments if necessary. A researcher or trained research assistant conducts the semi-structured interview. Training consists of a presentation of the research protocol and instructions on each questionnaire followed by role-play. To increase reliability, researchers follow an interview protocol. Weekly meetings are organized with the research team to discuss possible ambiguous answers.

**Primary outcome**

The primary outcome of this study is to estimate the difference in the mean QRISK3 score of patients receiving MULTI + compared to patients receiving TAU. QRISK3 is an algorithm that estimates the probability of developing cardiovascular disease over the next 10 years [43].

**Secondary outcomes**

Below we describe the measurement instruments used in this study. The questionnaires, including a more detailed description and their psychometric properties can be found in the additional file on assessment instruments [see Additional file 1]. All questionnaires are administered in Dutch and all available Dutch versions of questionnaires are used.

**Routine screening data**

Routine screening data on somatic health, psychosocial functioning, substance use, medication use and PA is collected semi-annually in patients by trained HCPs.

Data on somatic health is used to calculate the QRISK3 score (i.e. HDL cholesterol, blood pressure, and BMI as calculated by dividing weight in kg by height in m²). Additionally, fasting glucose (mg/dL), triglycerides (mg/dL), weight (kg) and waist circumference are measured. Weight and waist circumference is measured to the first decimal (0.1 kg/cm) under the clothes at the level of the umbilicus (with the patient standing).

The Health of the Nations Outcomes Scale (HoNOS) is used to assess psychosocial functioning. The majority of patients will be measured with the HoNOS-12 [44]. The HoNOS 65+ [45] is used for ages 65 and above. The HoNOS-12 and HoNOS 65+ each have 12 items divided into four subscales.

Data on substance use is collected through routine questions about smoking (yes/no/stopped, if yes or stopped, how much on average; packyears are calculated), alcohol use (glasses per day, on average) and use of (soft)drugs (yes/no).

Medication related to cardiovascular health and diabetes, and psychotropic medication will be collected and converted into Defined Daily Dose (DDD) according the Anatomical Therapeutic Chemical Classification System from the World Health Organization (WHO) [46].

**Lifestyle factors**

**Physical Activity** The Physical Activity Vital Sign (PaVs) is used to examine PA [47]. The PaVs is a 2-item questionnaire to assess whether patients meet the Dutch exercise guidelines for aerobic activity (yes/no). The PaVs for patients is obtained from routine screening. The PaVs is also assessed in HCPs through the online survey at each measurement.

The Simple Physical Activity Questionnaire (SIMPAQ) [48] is used to measure PA in addition to the PaVs. The SIMPAQ is a 5-item questionnaire which provides more detailed information about PA as compared to the PaVs and contains an additional measure on sedentary behaviour. The SIMPAQ is assessed in both patients and HCPs at each measurement.
Diet and eating behaviour Diet will be assessed through a 24-h dietary recall (24HR) of all food and beverages consumed by patients. The Three Factor Eating Questionnaire-R18 (TFEQ-R18) is used to assess three domains of eating behaviour [49]. Diet and eating behaviour are assessed in patients at each measurement.

Sleep and sleep medication The Scales for Outcomes in Parkinson’s disease sleep (SCOPA-Sleep) is used to evaluate sleep [50]. Additionally, information about the use of sleep medication is gathered. The SCOPA-Sleep is assessed in patients at each measurement.

Mental health outcomes

Psychopathology The Brief Symptom Inventory (BSI) is used to measure symptoms of psychopathology [51]. The BSI consists of 53 items assessing nine symptom domains. The BSI is assessed in patients at each measurement.

Quality of life Quality of life is measured with the EuroQol-5D (EQ-5D) [52] and the World Health Organisation Quality of Life-BREF (WHOQoL-BREF) [53]. The EQ-5D consists of five dimensions of health, with one item per dimension. The WHOQoL-BREF consists of four domains, measured through 24 items supplemented with two general health items. The EQ-5D is often used complementary to other quality of life instruments [54]. The EQ-5D and WHOQoL-BREF are assessed in patients at each measurement.

Positive mental health The Mental Health Continuum – Short Form (MHC-SF) is used to examine positive mental health [55]. The MHC-SF measures positive mental health with 14 items, representing three domains of well-being. The MHC-SF is assessed in patients at each measurement.

Implementation factors

Barriers and facilitators Barriers and facilitators regarding the implementation of MULTI+ are assessed with the Measurement Instrument for Determinants of the Innovation (MIDI) [56]. This questionnaire consists of 29 items divided into four scales, which can be adapted to measure relevant constructs for the implementation. The MIDI can be used to identify which determinants influence the use of an innovation and improve or establish an implementation strategy. The MIDI is conducted in patients and HCPs, because both groups are considered end-users of MULTI+. The questions are adapted to fit the different end-users according to the manual. MIDIs are conducted in HCPs and patients before the implementation (Pre-MIDI) and after the implementation (Post-MIDI) of MULTI+. Thus, there are four different MIDIs available.

Process evaluation To evaluate the implementation process and assess whether MULTI+ is delivered as intended, a process evaluation will be conducted using the RE-AIM framework [57]. RE-AIM stands for the reach, effectiveness, adoption, implementation, and maintenance, and is often used to better interpret the effectiveness and implementation of an innovation. Data is continuously gathered from multiple sources, such as the facility services, patient files, questionnaires, and observations from research assistants.

Adverse events Adverse events are investigated with an institutional program in which HCPs report and categorise incidents.

Motivation for behavioural regulation Individual HCP factors, such as self-determined motivation, may influence the promotion of a healthy lifestyle in patients [58]. To assess motivation for behavioural regulation in exercise, the Behavioural Regulation in Exercise Questionnaire (BREQ-2) is used [59]. The BREQ-2 is comprised of 19 items divided into five scales. Furthermore, the BREQ-2 is used to devise a questionnaire assessing the motivation for Behavioural Regulation in Diet Questionnaire (BRDQ). All items used in the BREQ-2 assessing behavioural regulation in exercise were converted by changing the word “exercise” to “(eat a) healthy diet”. Both versions of the BREQ-2 are assessed in HCPs at each measurement.

Health Technology Assessment (HTA) Cost-effectiveness is investigated through calculation of the costs of TAU as compared to costs of MULTI+. This social cost benefit analysis uses data from patient files to determine the costs of care used in the different conditions (TAU vs. MULTI+), and medication costs based on DDDs. Additionally, for the subgroup that answered questions regarding quality of life, we investigate impact on quality of life as opposed to costs. The total costs per measuring moment per patient is used as an outcome measure and expressed in euros.

Research procedures

Recruitment The implementation team informs the HCPs about the measurement procedures. Patients are informed about the study through HCPs and members of the implementation team (see Table 3 for participant timeline).
Promotion materials will be used (such as videos, flyers and posters) to give information about the study.

**Informed consent**
Informed consent of HCPs is obtained online. With permission from the Medical Ethical Commission (METC), patients give verbal informed consent using a visual informed consent (VIC). A VIC is a visualisation of the goal and procedures of the study, and usage of personal data. The VIC makes information about the study easier to comprehend for patients. Researchers and research assistants are trained to conduct the informed consent procedure verbally. Patients will not be included in the study if they do not understand the information given, as deemed by HCPs or researchers.

**Procedural considerations**
The semi-structured interviews are conducted in a suitable place as determined by the researchers, HCPs and patients. If a patient is unable to adequately answer all questions, HCPs are asked for support when possible. If participating patients decease or discontinue inpatient treatment, they will not be included for further data collection. Data collected up until that point will be used for analyses. When patients withdraw consent, data already collected will be stored according to data protocol and Dutch law but will not be used for analyses or publications. After each measurement, 50 gift vouchers of 10 euros will be raffled among patients. HCPs will receive a small gift at ward level (such as a fruit basket or a water jug).

**Study status**
At the time of this manuscript submission data collection has commenced and final measurement is expected in August 2022.

**Statistical analyses**
Within each cluster-intervention period (cluster I and TAU, cluster I and MULTI+, cluster II and TAU, cluster II and MULTI+ etc.) we will analyse the QRISK3 of patients treated in that period. We select the last known measurements for each patient (longest exposure). For each of these measurements, the duration of exposure of patients in this cluster is calculated (date of last measurement minus day of entering this period). A proportion of patients will experience the switch in intervention during their stay. In such individuals, we will analyse both measurements reflecting the different conditions. The correlation of between subject measurements will be taken into account by adding a random effect for subjects. All QRISK3 data points will be analysed with mixed model analyses. We will analyse the logit transformed QRISK3 probabilities for similar reasons as in logistic regression, namely to avoid problems of estimating probabilities below 0 or above one and because it is more likely that the effect of treatment and other covariates on the outcome will be constant on the relative odds ratio scale.

The linear mixed model will contain: treatment (binary, 1/0 coding), cluster (categorical, two levels, dummy variables), time period (categorical, four levels, dummy variables), random effect for subject, the duration of exposure (continuous, restricted cubic splines with three knots); and the following potential confounding variables: age (continuous), key diagnostic subgroups (categorical) and illness severity (continuous).

Multiple imputation will be used to account for missing values. The same variables will be used in the imputation model as in the analysis model, extended with characteristics related to these variables. Multiple imputation based on chained equations will be used to generate 10 imputation sets (or more if the number of missing values
is larger than expected). Results from imputed datasets will be pooled using Rubin’s rules.

Although MULTI will be integrated into routine clinical care regardless of specific inpatient facility setting, we pragmatically set a minimum of 10 days exposure, assuming we cannot expect an effect within a few days of hospitalization.

Explorative subgroup analyses will be performed to gain insight in possible treatment differences between the subgroups gender (categorical) age (continuous) and subjects with repeated-measures. Subgroup analyses will be performed consecutively by adding the main effect of these variables and their interaction to the main model specified above.

All analyses will be conducted with IBM SPSS statistics 25 and R version 4.0.4 or higher, with a 95% confidence interval (p < 0.05) and will be corrected for multiple outcomes/comparisons (Bonferroni correction) if necessary.

Sample size
Our sample size considerations are based on demonstrating a difference in body weight between conditions. The reason is that we did not have any relevant data on changes in QRISK3 for this population, whereas body weight has been used in our previous research [32]. Furthermore, body weight is a key component of the QRISK3 and, given the nature of MULTI, it is likely that other components of the QRISK3 will change in the same direction. Therefore, using body weight can be seen as a more robust and more conservative approach than using uncertain assumptions about changes in QRISK3.

Our research showed that 53.8% of the patients who participated in MULTI lost ≥ 5% of their initial bodyweight, as opposed to 16.3% of the patients who followed TAU. Given the broader implementation of MULTI, with patients who spend less time in healthcare than those in the earlier study, we expect to find effects in a relative smaller number of patients in this study. Based on a small-scale follow-up, we will assume 32% of patients will lose ≥ 5% of their initial bodyweight instead of 53.8%. Because metabolic risk factors are a routinely measured outcome, we expect a conservative dropout rate of 10%.

Because there is insufficient knowledge about the correlations between clusters, we will assume a correlation of 0.1. Based on these data, a power of 80%, a significance level of 5% (p < 0.05), three clusters, the minimal sample size should consist of 846 patients. Given the high patient turnover (n ≥ 2000), this seems feasible.

Data management
A data management protocol was created in which data entry, coding, security, and storage was recorded. Patient data is requested from the patient files through data

management officers of the institution. Data is pseudonymized which only researchers within the implementation team have access to. Data is only accessible through two-way factor authorization. Data is stored and protected for 20 years within the institution, in line with national privacy laws, and will not be made publicly available.

Discussion
This study protocol has been designed to evaluate the effectiveness and implementation of MULTI in a specialist mental healthcare organisation with ~ 830 places of residence. To our knowledge, this will be the first large-scale study evaluating the long-term effects of a multidisciplinary, multicomponent approach aimed at improving lifestyle factors in routine inpatient clinical care. This study builds on previous research, which showed improvements on both physical and mental health outcomes in patients, and the need for more organisational support to continue and expand its implementation [32].

A reduction of ≥ 5% loss of body weight is associated with a relevant reduction in cardiovascular risk [60], which we therefore originally considered as the primary outcome of this study [61]. However, this was reconsidered after observing the high-patient turnover hindering individual follow-up and several other substantive considerations. Predominantly, this outcome measure does not account for other known risk factors for developing CVD, such as familial history, age, smoking behaviour, total cholesterol level, presence of mental illness and the use of atypical antipsychotics. By not taking these risk factors into account, the risk of CVD is often underestimated in people with MI and outcomes can be misinterpreted (e.g., lack of weight loss while reducing smoking behaviour) [62]. QRISK3 is a risk calculator that estimates individual risk of developing CVD in people between 25–84 years old, using multiple predictor variables that are especially relevant for people with MI. Therefore, the primary aim of this study is to investigate the difference in the mean QRISK3 score of patients receiving MULTI compared to patients receiving TAU. To our knowledge there are no risk calculators suitable for ages under 25. Inpatients < 25 will therefore be excluded from this analysis, but will be included for secondary outcomes.

The study protocol should be viewed considering several limitations. A first limitation is the risk of missing data. For example, not all patients may be able to complete all questionnaires due to illness severity and cognitive deficits. Therefore, semi-structured interviews will be used to allow for more flexibility and clarification. Another reason for missing data could be patients
refusing the administration of the routine screening. Moreover, some routine measurements are only assessed on clinical indication, and will not be present for each patient.

Another limitation is that implementation monitoring could be a challenge because of the large-scale, real-world conditions of the study. Furthermore, external events and organisation-wide changes may impact the effectiveness and implementation of MULTI+ due to the non-controlled environment and may be difficult to account for.

Strengths of this study are that MULTI+ allows for pragmatic implementation in real-world settings through co-design and tailoring of the 10 core components. We expect that this approach will increase long-term sustainability and can serve as a potential blueprint. Additionally, studying implementation factors will expand our knowledge on how to overcome the implementation gap and successfully implement a lifestyle intervention. Furthermore, we research a broad spectrum of both physical and mental health outcomes in inpatients with MI. This dual research focus on both implementation factors and health outcomes will expand our knowledge on the possible influences these factors have on one another. Ultimately, we aim to improve routine clinical care for inpatients with mental illness.

Abbreviations
24HR: 24-Hour dietary recall; BMI: Body mass index; BRDQ: Behaviour regulation in diet questionnaire; BREQ-2: Behavioural regulation in exercise questionnaire-2; BS1: Brief symptom inventory; CM: Centimetres; CVD: Cardiovascular disease; DDO: Defined daily dose; EDC: Electronic data capture; EQ-SD: EuroQol-5d; HCPS: Health care professionals; HONOS: Health of the nation outcome scales; HTA: Health technology assessment; IC: Informed consent; KG: Kilograms; METC: Medical ethical committee; MG/DL: Milligrams per decilitre; MHC-SF: Mental health continuum-short form; MI: Mental illness; MIDI: Measurement instrument for determinants for innovations; MULTI+: Multidisciplinary lifestyle focused approach in the treatment of inpatients with mental illness; PA: Physical activity; PAVS: Physical activity vital sign; RCT: Randomized-controlled trial; SCOPA-SLEEP: Scales for outcomes in Parkinson’s disease-Sleep; SIMPAQ: Simple physical activity questionnaire; SM1: Severe mental illness; TAU: Treatment as usual; TFEQ-R18: Three factor eating questionnaire revised 18 items; VIC: Visual informed consent; WHO: World Health Organization; WHO-QOL: World health organization quality of life-bref.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12888-022-03801-w.

Additional file 1. Assessment instruments MULTI+.docx. Detailed description of measurement instruments and their psychometric properties.

Acknowledgements
In addition to the authors listed, the MULTI+ study is dependent on the continuous effort of the clients and health care professionals of the inpatient psychiatric wards of GGz Centraal. The authors would also like to thank Bianca Braakhuis for her ongoing work in the MULTI+ project and The Healthcare Innovation Center (THINC) and Mark Jan van Schothorst for their input.

Authors’ contributions
NB and MS contributed equally to the design of the study, the approach, and the drafting of the manuscript. IH, WC, PH and NV contributed to the study design and the drafting of the manuscript. JD designed the study, acquired funding and contributed to the drafting of the manuscript. The authors read and approved the final manuscript.

Funding
This work was supported by “Stichting tot Steun VCVGZ” grant number 277. The funding body did not contribute to the design of this study, collection of data, analysis and interpretation of data, and the writing of the manuscript.

Availability of data and materials
Because our data is pseudonymised, it is therefore still considered personal data. Future data is only available upon reasonable request from the corresponding authors.

Declarations
Ethical approval and consent to participate
The study protocol was approved by METC of the Isala Academy (case number 20033) and the institutional review board for scientific research of GGz Centraal. Informed consent is required to participate in this study for patients and HCPS. HCPS give written informed consent and patients give verbal informed consent. Both the written IC form and the verbal informed consent form and procedures were approved by the METC Isala Academy and the institutional review board for scientific research of GGz Centraal. Substantial protocol modifications will be submitted to the METC, subsidising party and institutional board.

Consent for publication
Not applicable.

Competing interests
None declared.

Author details
1 Scientific Research Department, GGz Centraal, Amersfoort, the Netherlands. 2 Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. 3 School for Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands. 4 Living Active, Santpoort-Zuid, the Netherlands. 5 Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands.

Received: 21 January 2022 Accepted: 19 February 2022
Published online: 31 March 2022

References
1. Hjorthøj C, Sturup AE, McGrath JJ, et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4:295–301. https://doi.org/10.1016/S2215-0366(17)30078-0.
2. Thomis G. Premature death among people with mental illness. BMJ. 2013;346:f3423. https://doi.org/10.1136/bmj.f3423.
3. Plana-Ripoll O, Weye N, Momen NC, et al. Changes over time in the differential mortality gap in individuals with mental disorders. JAMA Psychiatry. 2020;77:648–50. https://doi.org/10.1001/jamapsychiatry.2020.0334.
4. Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16:163–80. https://doi.org/10.1002/wps.20503.
5. Firth J, Siddiqi N, Koyanagi A, et al. The lancet psychiatry commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019;6:75–712. https://doi.org/10.1016/s2215-0366(19)30132-4.

6. Firth J, Solmi M, Wootton RE, et al. A meta-review of “lifestyle psychiatry”: the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatr. 2020;19:360–80. https://doi.org/10.1002/wps.20773.

7. Laursen TM, Plana-Ripoll O, Andersen PK, et al. Cause-specific life years worse? Schizophr Res. 2019;206:284–90. https://doi.org/10.1016/j.schres.2018.11.003.

8. Teasdale SB, Ward PB, Samaras K, et al. Dietary intake of people with severe mental illness: systematic review and meta-analysis. Br J Psychiat. 2019;214:251–9. https://doi.org/10.1192/bjp.2019.20.

9. Bak M, Drukker M, Cortenraad S, et al. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch: systematic review and meta-analysis of a meta-analysis. PLoS One. 2021;16:e0244944. https://doi.org/10.1371/journal.pone.0244944.

10. Barton BB, Segger F, Fischer K, et al. Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19:295–314. https://doi.org/10.1080/13596478.2020.1713091.

11. Firth J, Solmi M, Tiedemann A, Sherrington C. Physical activity interventions for people with mental illness: a systematic review and meta-analysis. J Clin Psychiat. 2014;75:694–70.

12. Stubbs B, Vancampfort D, Hallgren M, et al. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and position statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiat. 2018;54:124–44. https://doi.org/10.1016/j.eurpsy.2018.07.004.

13. Naslund JA, White H, McGhee J, et al. Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: a systematic review and meta-analysis. Gen Hosp Psychiatr. 2017;47:83–102. https://doi.org/10.1016/generhospsych.2017.04.003.

14. Teasdale SB, Ward PB, Njoroge G, et al. Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness. Br J Psychiat. 2017;210:110–8. https://doi.org/10.1192/bjp.bp.115.177139.

15. Gee B, Orchard F, Clarke E, et al. The effect of non-pharmacological sleep interventions on depression symptoms: a meta-analysis of randomised controlled trials. Sleep Med Rev. 2019;43:118–28. https://doi.org/10.1016/j.smrv.2018.09.004.

16. Povitz M, Bolo CE, Heitman SJ, et al. Effect of treatment of obstructive sleep apnea on depressive symptoms: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001762. https://doi.org/10.1371/journal.pmed.1001762.

17. Peckham E, Brabyn S, Cook L, et al. Smoking cessation in severe mental illness: what works? an updated systematic review and meta-analysis. BMC Psychiat. 2017;17:252. https://doi.org/10.1186/s12888-017-1410-7.

18. Stewart R. Mental disorders and mortality: so many publications, so little progress. Adverse Effect. 2015;12981.

19. Suetani S, Rosenbaum S, Scott J, et al. Bridging the gap: What have we done and what can we do to reduce the burden of avoidable death in people with psychotic illness? Epidemiol Psychiatr Sci. 2016;25:205–10. https://doi.org/10.1017/s2045796015001043.

20. Deenik J, Czesnink L, Teasdale SB, et al. From impact factors to real impact: translating evidence on lifestyle interventions into routine mental health care. Transl Behav Med. 2020;10:1070–3. https://doi.org/10.1093/tb/mbaa267.

21. Carney R, Intram S, Law H, et al. Physical health interventions on adolescent mental health inpatient units: a systematic review and call to action. Early Interv Psychiatr. 2020;15:439–48. https://doi.org/10.1111/epi.12981.

22. Koorts H, Eakin E, Estabrooks P, et al. Implementation and scale up of population physical activity interventions: a review of the published literature. Int J Behav Nutr Phys Act. 2018;15:1–11. https://doi.org/10.1186/s12966-018-0678-0.

23. Lennox L, Maher L, Reed J. Navigating the sustainability landscape: a systematic review of sustainability approaches in healthcare. Implementation Sci. 2018;13:1–17. https://doi.org/10.1186/s13012-017-0707-4.

24. Huebchmann AG, Leavitt IM, Glasgow RE. Making health research matter: a call to increase attention to external validity. Annu Rev Public Health. 2019;40:45–63. https://doi.org/10.1146/annurev-publhealth-040218-043945.

25. Brown CH, Curran G, Palinkas LA, et al. An overview of research and evaluation designs for dissemination and implementation. Annu Rev Public Health. 2017;38:1–22. https://doi.org/10.1146/annurev-publhealth-031816-044215.

26. Green LW, Nasser M. Furthering dissemination and implementation research. Dissemination and implementation research in health: Translating science to practice. 2017;301 doi:https://doi.org/10.1093/oso/9780190683214.003.0018.

27. Firth J, Ward PB, Stubbs B. Editorial: Lifestyle Psychiatry. Front Psychiatr. 2019;5:1059. https://doi.org/10.3389/fpsyt.2019.00597.

28. Deenik J, Deenik J, Thinking inside the box: changing lifestyle to improve the health status of inpatients with severe mental illness. 2019. https://doi.org/10.26481/dis.20190522y.

29. Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr Bull. 2015;39:306–18. https://doi.org/10.1093/schbul/bdv148.

30. Deenik J, Tenback DE, Tak EC, et al. Changes in physical and psychiatric health after a multidisciplinary lifestyle enhancing treatment for inpatients with severe mental illness. The MULTI study I. Schizophr Res. 2019;204:360–7. https://doi.org/10.1016/j.schres.2018.07.033.

31. Deenik J, Tenback DE, Tak EC, et al. Improved psychosocial functioning and quality of life in inpatients with severe mental illness receiving a multidisciplinary lifestyle enhancing treatment. The MULTI study II. Ment Health Phys Act. 2018;15:145–52. https://doi.org/10.1016/j.mhpa.2018.10.004.

32. Hemming K, Haines TP, Chilton PJ, et al. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ. 2015;350:h391. https://doi.org/10.1136/bmj.h391.

33. Blase K, Fixsen D. Core Intervention Components: Identifying and Operationalizing What Makes Programs Work. US Department of Health and Human Services: ASPe Research Brief; 2013.

34. McTeague LM, Goodkind MS, Etkin A. Transdiagnostic impairment of temperament: a call to increase attention to external validity. Annu Rev Public Health. 2019;40:45–63. https://doi.org/10.1146/annurev-publhealth-040218-043945.

35. McTeague LM, Goodkind MS, Etkin A. Transdiagnostic impairment of control in mental illness. J Psychiatr Res. 2016;83:37–46. https://doi.org/10.1016/j.jpsychires.2016.08.001.

36. Hippisley Cox J, Coupland C, Brindle P. Development and validation of a clinical decision rule: the QOF risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099. https://doi.org/10.1136/bmj.j2099.

37. Wing J, Bleeve A, Curtis R, et al. Health of the nation outcome scales (HoNOS). Br J Psychiat. 1998:172:1–11. https://doi.org/10.1192/bjp.172.1.11.
45. Burns A, Beevor A, Lelliott P, et al. Health of the Nation Outcome Scales for Elderly People (HoNOS 65+): glossary for HoNOS 65+ score sheet. Br J Psychiat. 1999;174:435–8. https://doi.org/10.1192/bjp.174.5.435.

46. WHO. WHO Collaborating Centre for Drug Statistics Methodology: Guidelines for ATC classification and DDD assignment. Oslo: WHO Collaborating Centre for Drug Statistic Methodology; 2021.

47. Greenwood JL, Joy EA, Stanford JB. The physical activity vital sign: a primary care tool to guide counseling for obesity. J Phys Act Health. 2010;7:571–6. https://doi.org/10.1123/jpah.7.5.571.

48. Rosenbaum S, Morell R, Abdel-Baki A, et al. Assessing physical activity in people with mental illness: 23-country reliability and validity of the simple physical activity questionnaire (SIMPAQ). BMC Psychiat. 2020;20:108. https://doi.org/10.1186/s12888-020-2473-0.

49. Karlsson J, Persson L-O, Sjöström L, et al. Psychometric properties and factor structure of the Three-Factor Eating Questionnaire (TFEQ) in obese men and women. Results from the Swedish Obese Subjects (SOS) study. Int J Obes. 2000;24:1715–25. https://doi.org/10.1038/sjijo.0801442.

50. Marinus J, Visser M, van Hilten JJ, et al. Assessment of sleep and sleepiness in parkinson disease. Sleep. 2003;26:1049–54. https://doi.org/10.1093/sleep/26.8.1049.

51. Derogatis LR, Melisaratos N. The brief symptom inventory: an introductionary report. Psychol Med. 1983;13:595–605. https://doi.org/10.1017/S0033291700804807.

52. Prieto L, Sacristan J, Hormaechea J, et al. Psychometric validation of a generic health-related quality of life measure (EQ-SD) in a sample of schizophrenic patients. Curr Med Res Opin. 2004;20:827–35.

53. WHO. WHOQOL-BREF: introduction, administration, scoring and generic version of the assessment: field trial version. WHO; 1996.

54. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72. https://doi.org/10.1016/0168-8510(96)00822-6.

55. Keyes C. The mental health continuum: from languishing to flourishing in life. J Health Soc Behav. 2002;43:207–22. https://doi.org/10.2307/3090197.

56. Fleuren MA, Paulussen TG, Van Dommelen P, et al. Towards a measurement instrument for determinants of innovations. Int J Qual Health Care. 2014;26:501–10. https://doi.org/10.1093/intqhc/mzu060.

57. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89:1322–7. https://doi.org/10.2105/AJPH.89.9.1322.

58. Mahony R, Blake C, Matthews J, et al. Physical activity levels and self-determined motivation among future healthcare professionals: utility of the Behavioral Regulation in Exercise Questionnaire (BREQ-2). Physiother Theory Pract. 2018;35:884.

59. Markland D, Tobin V. A modification to the behavioural regulation in exercise questionnaire to include an assessment of amotivation. J Sport Exerc Psychol. 2004;26:191–6. https://doi.org/10.1123/jsep.26.2.191.

60. Brown JD, Buscemi J, Milsom V, et al. Effects on cardiovascular risk factors of weight losses limited to 5–10%. Transl Behav Med. 2016;6:339–46. https://doi.org/10.1007/s13142-015-0353-9.

61. Evaluation of a multidisciplinary lifestyle treatment for inpatients with mental illness. https://ClinicalTrials.gov/show/NCT04922749.

62. Cunningham R, Poppe K, Peterson D, et al. Prediction of cardiovascular disease risk among people with severe mental illness: a cohort study. PLoS One. 2019;14:e0221521. https://doi.org/10.1371/journal.pone.0221521.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.